Skip to content

Aurion Biotech Wins “Best in Show” at AAO Eyecelerator Conference

Innovation in Ophthalmology Award Given to Most Promising Companies at Annual American Academy of Ophthalmology Meeting

November 12, 2021 – Seattle, Boston and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has received “best in show” for cornea innovators at the Eyecelerator conference, which inaugurates the annual American Academy of Ophthalmology meeting, held this year in New Orleans.

“I’m proud to be a part of the fantastic team at Aurion Biotech, who earned this prestigious award,” said Greg Kunst, chief executive officer at Aurion Biotech. “This award is an acknowledgement of the transformational potential of our therapy to restore vision to millions of patients suffering from corneal endothelial blindness.”

The company’s first candidate in development is a cell therapy for the treatment of corneal endothelial dysfunction, invented by leading ophthalmic surgeon and research scientist Professor Shigeru Kinoshita and his distinguished colleagues at Kyoto Prefecture University of Medicine (KPUM) in Japan. 

About Aurion Biotech

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In early research, dose ranging and confirmatory clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness. The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, a division of CorneaGen Inc., visit 

Media Contacts:

Judith McGarry


[email protected]

Michele Gray


[email protected]